Travere Therapeutics, Inc. - 8-K Filing
Travere Therapeutics appoints Bradley Campbell as CEO effective December 1, 2026; Eric Dube will step down but continue in advisory roles through February 2027. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 9.01 Financial Statements and Exhibits)
Tickers: $TVTX